Article Text

Download PDFPDF

A prospective trial of adjuvant therapy for high-risk uveal melanoma: assessing 5-year survival outcomes
  1. Elaine Binkley1,
  2. Pierre L Triozzi1,2,
  3. Lisa Rybicki3,
  4. Susan Achberger3,
  5. Wayne Aldrich3,
  6. Arun Singh1
  1. 1 Department of Ophthalmic Oncology, Cleveland Clinic, Cole Eye Institute, Cleveland, Ohio, USA
  2. 2 Department of Hematology Oncolgy, Wake Forest University, Winston Salem, North Carolina, USA
  3. 3 Department of Ophthalmic Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Correspondence to Dr Arun Singh, Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH 44106, USA; singha{at}


Background/aims Survival after diagnosis of metastasis from uveal melanoma is poor. Identifying individuals at high risk for metastasis and developing adjuvant therapy to prevent clinically apparent metastasis could improve survival. We conducted an adjuvant trial of sequential, low-dose dacarbazine (DTIC) and interferon-alpha-2b (IFN-α−2b) in patients with cytogenetic high-risk uveal melanoma.

Methods Patients diagnosed with iris, ciliary body or choroidal melanoma with high-risk tumour cytogenetics (monosomy 3) were offered adjuvant treatment with low-dose DTIC and IFN-α−2b following primary therapy. Eligible but not enrolled patients were observed for comparison. DTIC was administered at 850 mg/m2 intravenously on days 1 and 28. IFN-α−2b was administered at 3 million units three times a week subcutaneously for 24 weeks beginning at week 9. Hepatic imaging was performed prior to adjuvant therapy and then at least every 6 months. Survival data were collected for 5 years after enrolment.

Results 33 patients (22%) were enrolled (treatment group), 29 (19%) were eligible but did not enrol (observation group) and 88 (59%) were not eligible. The 5-year metastasis-free survival (MFS) was 64%±9% for treated and 33%±10% for observed patients (p=0.05). The 5-year overall survival (OS) rate was 66%±9% for treated and 37%±10% for observed patients (p=0.02).

Conclusions When adjusted for differences in age, tumour size and initial treatment, survival between treated and observed patients was no longer significant (p=0.56 MFS and p=0.92 OS). Differences in baseline tumour characteristics between treated and observed patients can influence interpretation of results.

Trial registration number NCT01100528.

  • uveal melanoma
  • adjuvant therapy
  • metastasis
View Full Text

Statistics from


  • Contributors EB: Data interpretation, drafting, critical revision manuscript. PLT: Study design, data acquisition, data interpretation, drafting manuscript. LR: Data analysis and interpretation, critical revision of manuscript. SA: Data analysis and interpretation. WA: Data analysis and interpretation. AS: Study design, data acquisition, data interpretation, drafting and critical revision of manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Obtained.

  • Ethics approval This study was approved by the Institutional Review Board (IRB) at the Cleveland Clinic and Case Comprehensive Cancer Centre (note that the study was conducted at the Taussig Cancer Centre at the Cleveland Clinic, there is a combined IRB for the cancer centres at the Cleveland Clinic and Case Western Reserve University).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost B Jonas